BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 12, 2004
 |  BioCentury  |  Emerging Company Profile

Revotar: Sum of the parts

Only rarely does a company's restructuring produce enough spare parts to create a separate, viable company. Revotar Biopharmaceuticals AG was created in 2000 as an Encysive Pharmaceuticals Inc. subsidiary to do research on inflammation. But after a restructuring by ENCY early in 2003, Revotar gained new intellectual property that provided the capability to strike out on its own.

Revotar begins life with a Phase II inflammatory compound for multiple indications and plans to fill its pipeline by in-licensing targets and applying its expertise in inflammation, rational drug design, and preclinical and early clinical development.

ENCY (formerly Texas Biotechnology Corp., Houston, Texas) restructured last January to focus on late-stage compounds. Shortly afterwards, Revotar received exclusiveworldwiderights, with the exception of topical applications in North America, for...

Read the full 625 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >